FacebookTwitterGoogle+RedditEmail

Big Pharma’s Profiteers: You Want Us to Pay What for These Meds?

by

It is no secret that the pill profit party is over for drug companies. Bestselling pills like Lipitor, Seroquel, Zyprexa, Singular, Concerta, Cymbalta and Abilify have gone off patent and Wall Street is moving on to industries that offer better returns.

To combat investor disenchantment, drug companies have rolled out expensive drugs that treat such rare conditions,  they almost sound like satire. If you are sleepy during the day, you may have narcolepsy says Jazz Pharmaceuticals which its drug Xyrem treats for $35,000 per year.  If you have frequent diarrhea, gas and bloating, you may have exocrine pancreatic insufficiency says AbbVie to sell the drug Creon.

Drug makers are even not above scaring the populace if it sells drugs for rare diseases. Your back pain may not be from working out at all but from a disease called ankylosing spondylitis, says AbbVie, a condition that can be treated with its biologic drug Humira for as much as $20,000 a year. (Injectable “biologic” drugs are a new drug industry push because they are so expensive and less susceptible to generic competition than pills.)

The drug industry is also trying to stay a Wall Street darling with new, uber priced drugs—notably hepatitis C drugs. Gilead Sciences sold $12.4 billion worth of Sovaldi at $1000 a pill last year, reports the New York Timesstraining the budgets of insurance companies and Medicaid programs.”

While drug company representatives initially tried to cast the outrageous prices as recouping martharosenbergtheir research and development costs they quickly back pedaled into admitting the drugs are priced on “value”—what they are “worth” for the patient’s health. Needless to say such valuations come pretty close to the definition of extortion—or offers you “can’t refuse.”

Even business writers cry foul. Why does the same hepatitis C drug that costs $84,000 a year in the US cost $900 a year in Egypt asked Forbes staff writer Avik Roy. Since most hepatitis C patients in the US are uninsured, underinsured or imprisoned, taxpayers pick up the bill through Medicaid, the VA and prison systems writes Roy.

Now Sanofi and Regeneron Pharmaceuticals are rolling out a cholesterol lowering drug which could be embraced by the millions who made the statin Lipitor the best selling drug in the world before it went off patent. Yet the list price of Praluent, an injectable biologic, is over $14,600 a year.  Like Gilead, Sanofi and Regeneron say the price reflects what it is worth in potential benefits to patients and savings to the health care system—e.g. what they can get.

Nor is cost the only question with the new cholesterol drug. Increasingly, high bad cholesterol is viewed as a weak cardiovascular risk factor versus other factors like inflammation. Cholesterol lowering drugs can also be used to duck important lifestyle changes. “Plenty of adults down statins regularly and shine off healthy eating because they know a cheeseburger and steak can’t fool a statin,” writes Dr. Michael J. Breus on the Huffington Post.

Luckily, lawmakers are demanding cost breakdowns from drug companies on the new four-digit priced drugs.  How much are true costs and what is profiteering? Some states are drafting bills that would allow insurers to refuse to pay for a drug if the manufacturer did not file the required cost breakdown reports.

What is the response of drug makers to bills addressing expensive drugs?  They would be costly to comply with, they say.

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

More articles by:

CounterPunch Magazine

minimag-edit

August 30, 2016
Russell Mokhiber
Matt Funiciello and the Giant Sucking Sound Coming Off Lake Champlain
Mike Whitney
Three Cheers for Kaepernick: Is Sitting During the National Anthem an Acceptable Form of Protest?
Alice Bach
Sorrow and Grace in Palestine
Sam Husseini
Why We Should All Remain Seated: the Anti-Muslim Origins of “The Star-Spangled Banner”
Richard Moser
Transformative Movement Culture and the Inside/Outside Strategy: Do We Want to Win the Argument or Build the Movement?
Nozomi Hayase
Pathology, Incorporated: the Facade of American Democracy
David Swanson
Fredric Jameson’s War Machine
Jan Oberg
How Did the West Survive a Much Stronger Soviet Union and Warsaw Pact?
Linda Gunter
The Racism of the Nagasaki and Hiroshima Bombings
Dmitry Kovalevich
In Ukraine: Independence From the People
Omar Kassem
Turkey Breaks Out in Jarablus as Fear and Loathing Grip Europe
George Wuerthner
A Birthday Gift to the National Parks: the Maine Woods National Monument
Logan Glitterbomb
Indigenous Property Rights and the Dakota Access Pipeline
National Lawyers Guild
Solidarity with Standing Rock Sioux Tribe against Dakota Access Pipeline
Paul Messersmith-Glavin
100 in Anarchist Years
August 29, 2016
Eric Draitser
Hillary and the Clinton Foundation: Exemplars of America’s Political Rot
Patrick Timmons
Dildos on Campus, Gun in the Library: the New York Times and the Texas Gun War
Jack Rasmus
Bernie Sanders ‘OR’ Revolution: a Statement or a Question?
Richard Moser
Strategic Choreography and Inside/Outside Organizers
Nigel Clarke
President Obama’s “Now Watch This Drive” Moment
Robert Fisk
Iraq’s Willing Executioners
Wahid Azal
The Banality of Evil and the Ivory Tower Masterminds of the 1953 Coup d’Etat in Iran
Farzana Versey
Romancing the Activist
Frances Madeson
Meet the Geronimos: Apache Leader’s Descendants Talk About Living With the Legacy
Nauman Sadiq
The War on Terror and the Carter Doctrine
Lawrence Wittner
Does the Democratic Party Have a Progressive Platform–and Does It Matter?
Marjorie Cohn
Death to the Death Penalty in California
Winslow Myers
Asking the Right Questions
Rivera Sun
The Sane Candidate: Which Representatives Will End the Endless Wars?
Linn Washington Jr.
Philadelphia District Attorney Hammered for Hypocrisy
Binoy Kampmark
Banning Burkinis: the Politics of Beachwear
Weekend Edition
August 26, 2016
Friday - Sunday
Louisa Willcox
The Unbearable Killing of Yellowstone’s Grizzlies: 2015 Shatters Records for Bear Deaths
Paul Buhle
In the Shadow of the CIA: Liberalism’s Big Embarrassing Moment
Rob Urie
Crisis and Opportunity
Charles Pierson
Wedding Crashers Who Kill
Richard Moser
What is the Inside/Outside Strategy?
Dirk Bezemer – Michael Hudson
Finance is Not the Economy
Jeffrey St. Clair
Roaming Charges: Bernie’s Used Cars
Margaret Kimberley
Hillary and Colin: the War Criminal Charade
Patrick Cockburn
Turkey’s Foray into Syria: a Gamble in a Very Dangerous Game
Ishmael Reed
Birther Tries to Flim Flam Blacks  
Brian Terrell
What Makes a Hate Group?
Andrew Levine
How Donald Trump Can Still be a Hero: Force the Guardians of the Duopoly to Open Up the Debates
Howard Lisnoff
Trouble in Political Paradise
Terry Tempest Williams
Will Our National Parks Survive the Next 100 Years?
FacebookTwitterGoogle+RedditEmail